Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A European Multi-Center, Multi-Country, Post-Authorisation, Observational Study (Registry) Of Patients With Hereditary Angioedema (HAE) Who Are Administered CINRYZE® (C1 Inhibitor [Human]) For The Treatment Or Prevention Of HAE Attacks

NCT01541423 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01541423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01541423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A European Multi-Center, Multi-Country, Post-Authorisation, Observational Study (Registry) Of Patients With Hereditary Angioedema (HAE) Who Are Administered CINRYZE® (C1 Inhibitor [Human]) For The Treatment Or Prevention Of HAE Attacks
Lead sponsor
Shire
Phase
Observational
Overall status
Completed
Start date
May 11, 2012
Completion date
September 25, 2016
Enrollment
83 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)